OS Therapies Incorporated
OSTX · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $125 | $113 | $1 | $1 |
| Gross Profit | -$125 | -$113 | -$1 | -$1 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,630 | $2,499 | $1,308 | $869 |
| G&A Expenses | $0 | $2,339 | $0 | $0 |
| SG&A Expenses | $3,124 | $2,339 | $3,690 | $2,096 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$113 | $0 | $0 |
| Operating Expenses | $6,755 | $4,726 | $4,999 | $2,965 |
| Operating Income | -$6,880 | -$4,839 | -$4,999 | -$2,966 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $302 | $1,123 | -$25 |
| Pre-Tax Income | -$6,880 | -$4,537 | -$3,877 | -$2,991 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6,880 | -$4,537 | -$3,877 | -$2,991 |
| % Margin | – | – | – | – |
| EPS | -0.21 | -0.18 | -0.18 | -0.04 |
| % Growth | -16.7% | 0% | -348.9% | – |
| EPS Diluted | -0.21 | -0.18 | -0.18 | -0.04 |
| Weighted Avg Shares Out | 31,957 | 25,114 | 21,249 | 123,773 |
| Weighted Avg Shares Out Dil | 31,957 | 25,114 | 21,249 | 123,773 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $8 |
| Depreciation & Amortization | $125 | $113 | $1 | $1 |
| EBITDA | -$6,755 | -$4,424 | -$3,876 | -$2,982 |
| % Margin | – | – | – | – |